Cargando…

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study

Abstract text: Background/Introduction: Chronic Myelomonocytic Leukemia (CMML) is an uncommon MDS/MPN overlap syndrome that has historically been included under the umbrella of myelodysplastic syndromes (MDS) for clinical trial and treatment. As a result, DNA methyltransferase inhibitors (DNMTi) suc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savona, Michael R., McCloskey, James K, Griffiths, Elizabeth A., Yee, Karen, Zeidan, Amer M., Al-Kali, Aref, Deeg, H. Joachim, Patel, Prapti, Sabloff, Mitchell, Keating, Mary-Margaret, Dao, Kim-Hien, Zhu, Nancy, Gabrail, Nashat, Fazal, Salman, Maly, Joseph, Odenike, Olatoyosi, Kantarjian, Hagop, DeZern, Amy E., O'Connell, Casey L., Roboz, Gail J., Busque, Lambert, Wells, Richard A., Amin, Harshad, Randhawa, Jasleen K., Leber, Brian, Hao, Yong, Keer, Harold N., Azab, Mohammad, Garcia-Manero, Guillermo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	637.Myelodysplastic Syndromes - Clinical and Epidemiological
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701430/ http://dx.doi.org/10.1182/blood-2021-154179

Ejemplares similares

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study
por: Garcia-Manero, Guillermo, et al.
Publicado: (2021)

P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES
por: Robert Savona, Michael, et al.
Publicado: (2023)

COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study
por: Padron, Eric, et al.
Publicado: (2021)

ANÁLISE DOS GRUPOS SANGUÍNEOS ABO E RH(D) EM PACIENTES COM COVID-19 QUE NECESSITARAM DE TRANSFUSÃO SANGUINEA
por: Machado, B.A., et al.
Publicado: (2020)

P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic
por: Feld, Jonathan, et al.
Publicado: (2020)

Immunogenicity of Covid-19 Vaccination in Subjects with Myelodysplastic Syndromes
por: Vidler, Jennifer, et al.
Publicado: (2021)

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine
por: Karantanos, Theodoros, et al.
Publicado: (2022)

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
por: Briski, Robert, et al.
Publicado: (2023)

Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020)

Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes
por: Fischer, Melissa A., et al.
Publicado: (2022)

High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes
por: Teichman, Jennifer, et al.
Publicado: (2022)

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
por: Valent, Peter, et al.
Publicado: (2019)

Decitabine/Cedazuridine: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer
por: Petrone, Giulia, et al.
Publicado: (2022)

Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation
por: Muto, Tomoya, et al.
Publicado: (2023)

Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometry
por: Clichet, Valentin, et al.
Publicado: (2023)

Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms
por: Badar, Talha, et al.
Publicado: (2023)

P727: REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS-M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS
por: Aguirre, Luis E., et al.
Publicado: (2023)

PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL
por: Shortt, Jake, et al.
Publicado: (2023)

Évaluation du risque chimique lié aux travaux de nettoyage et désinfection pendant la pandémie COVID-19 dans un hôpital public
por: Harrathi, Chayma, et al.
Publicado: (2022)

Correction to: Decitabine/Cedazuridine: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Mouse Models of CMML
por: Belotserkovskaya, Ekaterina, et al.
Publicado: (2021)

Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer
por: Crawford, Nyree, et al.
Publicado: (2021)

Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK
por: Murphy, Ravindhi, et al.
Publicado: (2023)

Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum
por: Calvo, Xavier, et al.
Publicado: (2022)

Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes
Publicado: (2022)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Bataller, Alex, et al.
Publicado: (2023)

Role of iron chelation in improving survival: An integral part of current therapy for myelodysplastic syndromes
por: Taran, Sachi Jain, et al.
Publicado: (2015)

High-risk MDS after HMAs
por: Adès, Lionel
Publicado: (2019)

The impact of spliceosome mutations in MDS
por: Boultwood, Jacqueline, et al.
Publicado: (2019)

The role of innate immunity in MDS pathogenesis
por: Sallman, David A., et al.
Publicado: (2019)

Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies
por: Pettit, Kristen, et al.
Publicado: (2015)

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
por: Verstovsek, Srdan, et al.
Publicado: (2016)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
por: Zeidan, Amer M., et al.
Publicado: (2023)

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
por: Yun, John Paul, et al.
Publicado: (2023)

The non‐peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis
por: Knoll, Gertrud, et al.
Publicado: (2021)

P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
por: Zeidan, Amer M., et al.
Publicado: (2023)

Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML).
por: Stark, A. N., et al.
Publicado: (1987)

Cannot write session to /tmp/vufind_sessions/sess_kojltalvu7oif85i4umrtpk5ce